Sarepta Therapeutics, Inc. (FRA:AB3A)

Market Cap	1.68B -84.6%
Revenue (ttm)	2.06B +47.1%
Net Income	-231.41M
EPS	-2.36
Shares Out	n/a
PE Ratio	n/a
Forward PE	10.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	45
Open	15.71
Previous Close	15.27
Day's Range	15.71 - 15.71
52-Week Range	8.96 - 103.70
Beta	n/a
RSI	45.72
Earnings Date	Feb 25, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 1,372
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AB3A

Financial Performance

Financial numbers in USD